Evommune, Inc. (EVMN) Discusses In Licensing of EVO570 for Autoimmune Diseases Prepared Remarks Transcript
Evommune, Inc. (EVMN) Discusses In Licensing of EVO570 for Autoimmune Diseases Prepared Remarks Transcript
Seeking Alpha11/6/2026Neutral
EVMN
Evommune, Inc.NYSEHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$241.34M
P/E Ratio
—
EPS
$-3.75
Beta
—
52W High
$33.20
52W Low
$4.94
50-Day MA
$8.16
200-Day MA
$17.51
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Evommune, Inc.
Evommune, Inc. is an innovative biotechnology company focused on developing cutting-edge therapeutics for immunological disorders, targeting significant unmet medical needs in this critical sector. With a promising pipeline and advanced research methodologies, Evommune is positioned to enhance immune response and improve patient outcomes. The company aims to establish a leading presence in the evolving immunotherapy market through its commitment to robust scientific practices and strategic partnerships. As it progresses through clinical trials, Evommune is striving to deliver transformative solutions that could redefine the standards of care in immunology, thereby significantly impacting patient quality of life.
Fundamentals
| Revenue (TTM) | $10.00M |
| Gross Profit (TTM) | $10.00M |
| EBITDA | $-100.36M |
| Operating Margin | -1019.00% |
| Return on Equity | -52.10% |
| Return on Assets | -32.00% |
| Revenue/Share (TTM) | $0.44 |
| Book Value | $7.65 |
| Price-to-Book | 0.83 |
| Price-to-Sales (TTM) | 24.13 |
| EV/Revenue | 3.85 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $36.29M |
| Float | $19.88M |
| % Insiders | 3.16% |
| % Institutions | 110.90% |
Historical Volatility
HV 10-Day
126.73%
HV 20-Day
108.58%
HV 30-Day
99.71%
HV 60-Day
89.76%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($22.33 target)
4
Strong Buy5
Buy2
HoldLatest News
Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky
Evommune stock dropped approximately 38% after EVO756 missed its Phase 2b primary endpoint in chronic spontaneous urticaria, erasing millions in shareholder value in a single session. NEW YORK, July 7, 2026 /PRNewswire/ -- Evommune, Inc. (NYSE: EVMN) shareholders lost approximately 38% of their investment value on June 29, 2026, when the Company disclosed that its lead drug candidate EVO756 failed to meet the primary endpoint -- mean change in UAS7 at 12 weeks -- in its Phase 2b trial for moderate-to-severe chronic spontaneous urticaria (CSU).
PRNewsWire7/7/2026Neutral
Evommune's Healthy Balance Sheet Buys Them Time For AD
Evommune, Inc.'s recent miss with EVO756's CSU indications is a major setback. I agree that this creates doubts about the rest of EVMN's pipeline because the same biology now needs cleaner data in AD and migraine. However, remember that EVO301 still gives EVMN another catalyst after their positive Phase 2a AD data.
Seeking Alpha7/1/2026Positive
Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN)
Evommune's CEO and CSO sold shares on June 22, 2026, under Rule 10b5-1 plans adopted months earlier -- days before the Company disclosed that EVO756 failed its Phase 2b primary endpoint. NEW YORK, June 30, 2026 /PRNewswire/ -- Evommune, Inc. (NYSE: EVMN) shares dropped approximately 38% after the Company announced that its lead drug candidate EVO756 failed to meet the primary endpoint in a Phase 2b trial evaluating the treatment in adults with moderate-to-severe chronic spontaneous urticaria.
PRNewsWire6/30/2026Neutral
EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal
Evommune shares fall after its phase IIb CSU study misses the primary endpoint, prompting the company to halt further development of EVO756 for the indication.
Zacks Investment Research6/30/2026Negative
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results from its randomized, double-blind, placebo controlled, dose-ranging Phase 2b trial evaluating the efficacy and safety of oral MRGPRX2 antagonist, EVO756, in adults with moderate-to-severe chronic spontaneous urticaria (CSU).The Phas.
Business Wire6/29/2026Neutral
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a business update. “We continue to make meaningful progress across our broad chronic inflammation targeted pipeline and remain on track to deliver top-line Phase 2b data for.
Business Wire5/7/2026Neutral
Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcript
Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcript
Seeking Alpha4/14/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on EVMN and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 11/7/2026